Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Gilead | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Gilead

HCV sales slide 31% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Gilead

3Q Revenues: $7.5 billion (-10%)

3Q Earnings: $3.3 billion (-28%)

YTD Revenues: $23.1 billion (-4%)

YTD Earnings: $10.4 billion (-23%)

Comments: HIV and other antiviral product sales were $3.5 billion, up 21% primarily due to continued uptake of tenofovir alafenamide (TAF) based products, Genvoya, Descovy, and Odefsey. HCV product sales, which consist of Harvoni, Sovaldi, and Epclusa, were $3.3 billion down 31% due to lower sales of Harvoni and Sovaldi, partially offset by Epclusa sales, which was launched in the U.S. and Europe in June and July 2016, respectively. Other product sales, which include Letairis, Ranexa and AmBisome, were $564 million in the quarter, up 11%. R&D expenses were $1.1 billion in the quarter, up 54% primarily due to the overall progression of Gilead’s clinical studies, including a $200 million milestone expense associated with the purchase of Nimbus Apollo, Inc.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters